

Crizanlizumab

Cat. No.:	HY-P9987
CAS No.:	1690318-25-2
Target:	P-selectin
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease ^{[1][2][3]} .
IC ₅₀ & Target	P-selectin ^[2]
In Vivo	Crizanlizumab (1 or 6 mg/kg, i.p., 3 days a week for 5 months) improving sickle cell retinopathy in four weeks old male HbSS (sickle cell disease) mice ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Hannah A. Blair, et al. Crizanlizumab: First Approval. *Drugs*. 80, 79-84 (2020).
- [2]. Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. *N Engl J Med*. 2017 Feb 2;376(5):429-439.
- [3]. Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. *Investigative Ophthalmology & Visual Science* June 2023, Vol.64, 4747.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA